Article thumbnail

Association of Short Tandem Repeat Polymorphism in the Promoter of Prostate Cancer Antigen 3 Gene with the Risk of Prostate Cancer

By Wu Zhou, Zhanguo Chen, Wangqiang Hu, Mo Shen, Xiaoxia Zhang, Chengdi Li, Zhiliang Wen, Xiuling Wu, Yuanping Hu, Xiaohua Zhang, Xiuzhi Duan, Xiucui Han and Zhihua Tao
Topics: Research Article
Publisher: Public Library of Science
OAI identifier: oai:pubmedcentral.nih.gov:3105025
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2008). [Detection of urine DD3/PSA mRNA ratio by duplex TaqMan RT-PCR assay and evolution of its primary application].
  2. (1993). An assessment of radical prostatectomy. Time trends, geographic variation, and outcomes. The Prostate Patient Outcomes Research Team.
  3. (1999). Cancer statistics,
  4. (1999). DD3: a new prostate-specific gene, highly overexpressed in prostate cancer.
  5. (2009). DD3(PCA3) gene expression in cancer and prostatic hyperplasia.
  6. (2002). DD3(PCA3), a very sensitive and specific marker to detect prostate tumors.
  7. (2010). Differential display code 3 (DD3/PCA3) in prostate cancer diagnosis.
  8. (1993). Influence of capsular penetration on progression following radical prostatectomy: a study of 196 cases with long-term followup.
  9. (2000). Isolation and characterization of the promoter of the human prostate cancerspecific DD3 gene.
  10. (1994). Longterm (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer.
  11. (2010). PCA3 gene expression in prostate cancer tissue in a Chinese population: quantification by real-time FQ-RT-PCR based on exon 3 of PCA3.
  12. (2004). Prevalence of prostate cancer among men with a prostate-specific antigen level , or =4.0 ng per milliliter.
  13. (1997). Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control.
  14. (1990). Radical prostatectomy for clinical stage T1-2N0M0 prostatic adenocarcinoma: long-term results.